Furthermore, in this study, we have explored the relationship between the chosen measures, or their combinations, with the Expanded Disability Status Scale (EDSS) and the neurofilament light chain in the serum (sNfL), which are respectively (i) a clinical measure of disability in MS patients and (ii) a biological measure of neuroaxonal damage (Barro et al., 2018; Siller et al., 2019). This evidence concerns the gene NEFL and myeloid sarcoma.